A second-generation selective JAK1 inhibitor in canine atopic dermatitis: placebo-controlled, 61 dogs, 28 days

Veterinary Dermatology has published a multicentre, blinded, randomised, placebo-controlled trial of atinvicitinib, a second-generation highly selective JAK1 inhibitor, in client-owned dogs with canine atopic dermatitis (cAD).

Design. Sixty-one client-owned dogs, aged ≥ 12 months and weighing ≥ 2 kg, with cAD. Dogs received atinvicitinib with food at 0.8–1.2 mg/kg once daily for 28 days (q.d., n = 21); or 0.4–0.6 mg/kg twice daily for 14 days followed by once daily for 14 days (b.i.d.–q.d., n = 21); or placebo on the b.i.d.–q.d. schedule (n = 19). Owners scored pruritus on a visual analogue scale (PVAS) on days 0–7, 14 and 28; veterinary surgeons scored lesions using CADESI-04 on days 0 and 28. Blood and urine were sampled on days 0, 14 and 28. Success was defined as a ≥ 50% reduction from baseline in PVAS or CADESI-04 at day 28.

Results as reported. Success was 87.5% in the q.d. group (p = 0.011) and 73.3% in the b.i.d.–q.d. group (p = 0.033), against 23.1% in controls. A ≥ 2-point PVAS reduction occurred in 80.0% of q.d. dogs versus 16.7% of controls (p = 0.042). Reductions in PVAS were significantly greater than control in both active groups (q.d. p = 0.003; b.i.d.–q.d. p = 0.001), and in CADESI-04 for the q.d. group (p = 0.046). Mean clinical pathology values remained within reference ranges and the authors report the regimen was well tolerated.

What it establishes, and what it does not. The comparator is placebo, not an existing therapeutic option, so the trial supports no comparative positioning against current standards of care despite the "second-generation" designation. Group sizes of 19–21 are adequate to separate active from placebo and too small to characterise uncommon adverse events. The 28-day duration does not address long-term safety of JAK pathway inhibition in a condition managed over years. Mean laboratory values within reference ranges is a group-level statement. The owner-assessed primary measure is subjective, which the blinding is there to handle — the 23.1% placebo success rate indicates how much that matters.

Relevance for the category. The pharmacological arm of cAD management continues to consolidate around targeted immune-pathway inhibition, on schedules built for owner compliance. Nothing here bears on nutritional or barrier-directed approaches: no dietary or environmental variable was measured, and symptomatic control leaves allergen investigation, skin barrier care and secondary infection management untouched. The relevant observation for ingredient suppliers is that this literature is establishing what symptom control looks like as a benchmark, against which adjunctive positioning will be read.